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ABSTRACT 
In the more than 20 years since its discovery, both the phylogenetic origin and cellular 
function of the prion protein (PrP) have remained enigmatic. Insights into the function of 
PrP may be obtained through a characterization of its molecular neighborhood. 
Quantitative interactome data revealed the spatial proximity of a subset of metal ion 
transporters of the ZIP family to mammalian prion proteins. A subsequent bioinformatic 
analysis revealed the presence of a prion-like protein sequence within the N-terminal, 
extracellular domain of a phylogenetic branch of ZIPs. Additional structural threading 
and ortholog sequence alignment analyses consolidated the conclusion that the prion 
protein gene family is phylogenetically derived from a ZIP-like ancestor molecule. Our 
data explain structural and functional features found within mammalian prion proteins as 
elements of an ancient involvement in the transmembrane transport of divalent cations. 
The connection to ZIP proteins is expected to open new avenues to elucidate the biology 
of the prion protein in health and disease.   
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
09
.2
86
7.
1 
: P
os
te
d 
10
 F
eb
 2
00
9
  Page 3 
Prion diseases are fatal neurodegenerative diseases of humans and animals which, in 
addition to sporadic and familial modes of manifestation, can be acquired via an 
infectious route of propagation. Prion diseases include sporadic and variant forms of 
Creutzfeldt-Jakob disease in humans. In sheep, cattle, and cervids prion diseases manifest 
as scrapie, bovine spongiform encephalopathy, and chronic wasting disease, respectively. 
The normal, cellular prion protein (PrPC) is expressed at high levels in the central nervous 
system, but can also be found in other cell types within the body. In prion disease, PrPC 
undergoes a structural transition to its disease-causing form (PrPSc) which possesses 
profoundly different physicochemical properties1. 
The prion protein may constitute the most intensively studied mammalian protein. 
Yet surprisingly, the evolutionary origin and physiological function of this protein have 
remained largely elusive2, 3. The function of a protein can sometimes be inferred from 
genomic investigations which may reveal proteins with similar sequences or sequence 
modules of known function. Extensive investigations of this kind provided evidence for 
PrP-related sequences in most species of the vertebrate lineage4-6 and revealed two 
mammalian paralogous sequences encoding for the proteins Doppel (Dpl) and Shadoo 
(Sho), which together with PrPC constitute the mammalian prion protein family7. Despite 
these advances, no conclusive biological role has emerged for PrPC from the 
characterization of these additional members of the mammalian prion protein family8.  
Alternatively, by comparing the structural features of particular proteins, 
otherwise cryptic functional similarities may be inferred. Investigations of PrPC revealed 
an unusual dichotomy of its structure, which consists of an extended, largely unstructured 
N-terminus and a globular and relatively stable C-terminal domain formed by two β-
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strands and three α-helices9. While proteins with mixed β-strands and α-helices are 
widespread in nature, aside from Sho and Dpl which share structural features with the N-
terminal and C-terminal regions of PrP, respectively, no other protein has been identified 
to infer the physiological function of PrPC based on structural similarities. Extensive 
evidence has, however, been accumulated which demonstrates that the prion protein can 
bind a subset of divalent metal cations through two types of histidine-containing motifs 
embedded in its N-terminal domain.  
Most proteins do not act in isolation but partner with other proteins to exert their 
biological roles10. Thus, the function of a protein can sometimes be deduced by 
characterizing its binding partners. Following this ‘guilt-by-association’ logic, we set out 
to identify the function of the cellular prion protein through a comprehensive interactome 
investigation. Surprisingly, this work not only revealed novel interactors but also shed 
light on the evolutionary origins and an ancient function of members of the prion gene 
family.  
RESULTS 
Quantitative interactome analyses 
Various earlier attempts by us and others had already led to the identification of a 
few dozen proteins that co-purify with the cellular prion protein under a range of 
experimental conditions11. Often investigations of this kind result in long lists of 
candidate interactors. The challenge then remains to discriminate specific from unspecific 
binding partners. Here we incorporated quantitative mass spectrometry based on isotopic 
tagging of peptides into the workflow to overcome this limitation12. Furthermore, 
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investigations were extended to all three members of the mammalian prion protein family 
to further facilitate discrimination of potential interactors by differential interactome 
comparison. A murine neuroblastoma cell line (N2a), an established cell model for prion 
replication, served as the biological source material13. The cell line was stably transfected 
with a member of the mammalian prion protein family that had been FLAG-tagged in the 
vicinity of the N-terminus of the mature protein or with a negative control vector14. The 
conceptual choice of both the FLAG-tag and N-terminal attachment site was guided by 
data documenting that such insertions do not interfere with either PrPC processing or 
conversion in transgenic animals15, as well as studies of glycosylation and trafficking in 
Dpl- and Sho-transfected cells (J. Coomaraswamy et al., in preparation). To stabilize 
physiologically relevant interactions, adherent cells were crosslinked by a short treatment 
with formaldehyde prior to the cell harvest step16. Following cell lysis in the presence of 
detergents, crosslinked protein complexes were affinity-purified based on the presence of 
the FLAG-affinity tag, trypsinized in solution, and subjected to labeling with isobaric 
tags for relative and absolute quantitation (iTRAQ)17. The samples for the separate prion 
proteins and the control were mixed and jointly analyzed by tandem mass spectrometry. 
It should be noted that subsequent to iTRAQ conjugation, the contribution of each sample 
to the identification of a peptide can readily be calculated by determining the relative 
intensity of signature iTRAQ mass signals in the relevant collision induced dissociation 
(CID) spectra. A comprehensive analysis of samples led to the identification of 
approximately one hundred proteins, more than thirty of which were observed with 
iTRAQ signature mass intensity ratios that suggested specific co-enrichment with 
members of the prion protein family (Supplementary Fig. 1; a detailed description of 
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this large dataset will be presented elsewhere). Strikingly, two proteins, ZIP10 (slc39a10) 
and ZIP6 (slc39a6), which were unequivocally identified with non-overlapping peptides 
in Dpl, Sho and PrP samples but not in the negative control, represent members of the 
ZIP family (Zrt-, Irt-like Protein) of transmembrane proteins (Table 1). The slc39a gene 
family codes for fourteen distinct proteins (ZIP1-14) in humans. ZIP10 and ZIP6 
populate together with their phylogenetically closest paralog ZIP5 a subbranch within 
this family18.  
Structural and sequence similarities of mammalian prion proteins and ZIPs 
Intrigued by the presence of two phylogenetically related proteins, which we had 
never observed in similar datasets, the proteins were subjected to an extensive 
bioinformatic analysis. Surprisingly, the results revealed the presence of a domain within 
a subset of mouse ZIP proteins that displayed a substantial sequence similarity to both 
PrP and Dpl. The search was conducted with a SCOP (Structural Classification of 
Proteins, version 1.69)19 linear hidden Markov model (HMM; Superfamily model 
0037705) that had been trained on a multiple alignment of prion protein ortholog 
sequences (Superfamily 54098, designated as ‘Prion-like’)20. More specifically, a 107-
amino acid fragment within ZIP10 (residues 285 to 391) not only showed good general 
alignment with the C-terminal globular domain of mouse PrP (41% similarity), but 
demonstrated perfect positional agreement of both conserved cysteine residues (which 
form a disulfide bridge in PrPC) and the glycosylation site motif ‘NxT’ within that 
domain (Fig. 1a) (highly similar motifs were also found in ZIP6 and ZIP5). No other 
SCOP linear HMM model aligned to this region (from a total of 982 different models in 
this SCOP release). More importantly, aside from ZIPs and classical PrP family members 
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no other protein among the more than 120,000 mouse and human proteins represented in 
the LOCATE subcellular localization database (URL: http://locate.imb.uq.edu.au)21 is 
recognized by the ‘Prion-like’ linear HMM in this manner. To further assess the 
statistical significance of the sequence similarity between PrP and ZIPs within this 
domain, we applied a method for homology inference using profile-profile alignments 
embedded within an algorithm that can be initiated from the program COMPASS22. A 
query of this algorithm with the abovementioned mouse ZIP10 segment returned the 
SCOP40 database entry ‘Prion protein domain’ (designator d.6.1.1.) as the only hit (E-
value = 4.51e-4) which passed the statistical significance threshold of 5e-3, thereby 
classifying the respective domains within ZIPs and PrP as homologous.  
Proteins of common evolutionary origin are frequently characterized by similar 
folds. Well-studied examples include proteins of the immunoglobulin and fibronectin 
type III superfamilies. Such proteins are often the result of divergent evolution during 
which they have accumulated differences in their primary structure but continue to 
sustain similar folds. The comparison of protein structures therefore constitutes an 
orthogonal approach in studying the relationship of proteins. Whereas a multitude of 
high-resolution structures of prion proteins from many species have been solved, similar 
information is currently not available for metal ion transporters of the ZIP family. We 
therefore employed structural threading algorithms to assess the predicted similarity of 
the folds of PrP and Dpl and the respective ‘prion-like’ (PL) domain in ZIPs. This 
comparison was based on an analysis utilizing the FFAS03 fold and function assignment 
server23. The profile-based sequence alignment revealed prominent sequence similarities 
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between PrP, Dpl and ZIP10 (Fig. 1a), which allowed threading the sequence of the PL 
domain of ZIP10 onto the structures of both PrP and Dpl (Fig. 1b). 
Initially, the FFAS03 structural alignment scores with ZIP10 were just below the 
threshold for statistical significance with values around -9.0 and a threshold of -9.5 (with 
the threshold indicating less than 3% false positives). However, relatively small changes 
to the sequence of ZIP10 or by replacing it with its paralog ZIP5 did bring the FFAS03 
structural alignment scores into the statistically significant range (with values of -9.75 or 
below). Consistently, the models with the strongest scores were based on alignments of 
PL domains of ZIP proteins with mouse PrP or Dpl structures and all attempts to align the 
ZIP PL domain to structural templates outside the prion protein family produced 
insignificant fits. The PL domains of ZIP10 (and ZIP5, not shown) are predicted to 
contain a structural arrangement very similar to that of PrP or Dpl with three α-helices 
and possibly a short β-sheet composed of two β-strands (Fig. 1b). The root mean square 
deviation (RMSD) between backbone carbon atoms of the nuclear magnetic resonance 
(NMR) structures for PrP and Dpl is 3.7 Å (as determined by the DaliLite server24). 
Surprisingly, the RMSD between the predicted structure for the PL domain of ZIP10 and 
the PrP and Dpl structures returned even lower values of 2.6 Å and 2.9 Å, respectively, 
indicating that the primary structure of the ZIP10 PL domain is highly compatible with 
the basic prion protein fold. Consequently, this observation argues that the secondary 
structure elements of PrP and Dpl originated from similar structural features in the ZIP 
PL domain. 
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Convergent evolution versus common evolutionary origin 
It is well-established that similar secondary and tertiary protein structures can 
evolve independently, as is the case with structural similarity of prokaryotic subtilisin and 
eukaryotic chymotrypsin25. However, instances of convergent evolution at the protein 
sequence level are rare. Whenever reported, observations appear restricted to convergent 
adjustments of individual amino acids rather than independent evolutionary inventions of 
extensive blocks of similar primary structure. A frequently cited case represents the 
independent adaptation of the protein lysozyme to the acidic milieu found in the digestive 
tracts of unrelated species26. To investigate whether the similarities between PrPC and 
ZIP10 constitute a case of convergent evolution, we analyzed ortholog sequences of both 
PrPC and ZIP10 across a wide range of species within the chordate lineage. This was 
based on the conception that a divergent trend in sequence similarity would be indicative 
of a common phylogenetic ancestry, whereas the opposite scenario, in which the highest 
sequence similarity is seen in phylogenetically recent species, would constitute evidence 
for convergent evolution between PrPC and ZIP10 sequences. PrPC-related sequences can 
be found in all mammals and most species of the vertebrate lineage. ZIP proteins date 
back much further and are highly conserved throughout evolution. Related sequences can 
be found in all kingdoms of life, including bacteria and plants. The comparison of ZIP10 
ortholog sequences revealed the presence of a highly conserved ‘PALLY’ motif, also 
noted in ref. 18, within the domain resembling PrP sequences. This motif is not found in 
mouse or human PrPC sequences (Fig. 2a). Subsequently, the sequence alignment of PrP-
1 and ZIP10 from pufferfish (Takifugu rubripes) (i) not only revealed multiple additional 
amino acid residues conserved between pufferfish ZIP10 and PrP-1 — primarily in 
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highly conserved sequence positions (28% identity, 43% similarity); but also (ii) 
demonstrated the existence of the ‘PAL’ half motif within pufferfish PrP-1 in the 
expected location; and (iii) uncovered the presence of an extra cysteine in PrP-1 missing 
in mammalian prion proteins but present at the extracellular boundary of the first 
transmembrane domain in ZIP10 sequences from various species. A similar relationship 
was also observed between stickleback (Gasterosteus aculeatus) PrP-1 and ZIP10 
sequences. PrP sequences from chicken (Gallus gallus) and frog (Xenopus tropicalis), 
organisms that lie between fish and mammals on the evolutionary scale, gave 
intermediate percent identity values when aligned with the corresponding ZIP10 
sequences. In light of these data, convergence could be excluded as an explanation for the 
similarity of ZIP and PrPC sequences. Instead, this analysis firmly established an 
evolutionary common origin of ZIP transporters and PrPC.  
N-terminal duplication versus PL domain insertion 
Two alternative scenarios seemed plausible for the origin of modern day prion 
proteins: a gene rearrangement may have caused the insertion of the PL domain of a ZIP 
ancestor gene into a Sho-like precursor molecule thereby giving rise to a PrP founder 
gene. Alternatively, the complete PrP sequence including promoter elements and N-
terminal sequences could have originated from a ZIP ancestor molecule. If the latter had 
occurred, similarities between ZIP proteins and PrP should not be restricted to the PL 
domain but extend to other features. We therefore compared the known biological 
features of prion proteins and ZIP proteins of the phylogenetic branch comprising ZIPs 5, 
6 and 10. Both PrPC and ZIPs 6 and 10 share a widespread expression in biological 
tissues with high transcript levels in the brain18. The expression of ZIP5 is more restricted 
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and no ZIP5 transcripts can be found in N2a cells (data not shown). Reminiscent of N-
terminal repeat motifs in PrPC, ZIPs 5, 6 and 10 are equipped with histidine-rich repeat 
sequences N-terminal to their PL domains. Also reminiscent of PrPC, the PL domains 
within ortholog sequences of these ZIPs are more highly conserved than their N-terminal 
repeat sequences. The diversification of the latter is likely aided by an increased chance 
of unequal crossing-over recombination events generally associated with tandem repeat 
regions and previously suggested for prion sequences from different species6. The PL 
domains within ZIPs 5, 6 and 10 are part of their extracellular N-terminal domains and, 
with regard to orientation and relative distance to their downstream membrane anchorage 
sites, reminiscent of PrPC. Both PrPC and the above ZIPs are known to bind divalent 
metal ions through histidine-containing motifs embedded in N-terminal repeat 
sequences18, 27. While it is unknown whether PrPC’s metal binding ability serves a 
purpose for sensing, scavenging or transport of divalent cations in vivo , a role of the 
prion protein in the cellular zinc homeostasis has been proposed before28, and members 
of the ZIP protein family are well-characterized in their ability to transport zinc and other 
divalent metals across membranes. ZIPs 5, 6 and 10 reside, like PrPC, in the plasma 
membrane and are expected to facilitate metal import into the cytoplasm. Taken together, 
this context analysis uncovered multiple additional commonalities between ZIP proteins 
and PrPC consistent with the interpretation that these molecules are related beyond 
sequence similarities in their PL domains. Our observation that ZIP10 and ZIP6 co-
purified not just with FLAG-PrP and FLAG-Dpl but also with FLAG-Sho, as evidenced 
by strong iTRAQ117 signals in CID spectra which led to the identification of ZIP10 and 
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ZIP6, lent further support to this conclusion, because FLAG-Sho does not harbor a PL 
domain.  
To further investigate this question, we undertook a systematic comparison of N-
terminal sequences within and across the two protein families. Alignments of ZIP6 and 
ZIP10 with their closest phylogenetic neighbor ZIP5 suggested that N-terminal 
expansions of histidine-rich sequences present in ZIP6 and ZIP10 emerged following 
their divergence from a common ancestor with ZIP5. Thus, whereas ZIP5 shares the most 
conserved N-terminal sequence segments, it has a much shorter N-terminus and is only 
equipped with a short histidine cluster. Interestingly, the subsequent alignment of a Sho2 
sequence from pufferfish not only showed remarkable sequence conservation to ZIP5 
from zebrafish (34% identity, 41% similarity) but close examination revealed that a 
group of basic residues, the position of a largely hydrophobic sequence segment and the 
abovementioned cluster of histidines are shared between these sequences (Fig. 2b). The 
above sequence alignment falls on the empirical threshold which distinguishes instances 
of significant similarity from uncertain ‘twilight zone’ alignments29. Nonetheless, in the 
context of other similarities presented above, it corroborates the conclusion that the 
homology between ZIP and prion protein families extends beyond the globular domain 
present in PrP and Dpl to include sequences N-terminal to this domain, present in Sho.  
Having established the relation between prion and ZIP sequences, the order in 
which these molecules emerged during evolution could be deduced. Given that ZIP 
proteins are widespread in all kingdoms of life whereas PrPC and Sho appear restricted to 
species of the Chordata lineage, a parsimonious interpretation is that PrPC, and most 
likely Sho, evolved from a ZIP-like ancestor molecule. To sustain a viewpoint in favor of 
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a reverse phylogenetic relationship between these gene families it would be necessary to 
invoke a scenario in which prion gene sequences disappeared independently in most 
kingdoms of life except in vertebrates. 
Divergent development of prion and ZIP genes 
An in-depth analysis of the relative timing of the evolutionary origin of prion 
gene family sequences is beyond the scope of this article. Our current data suggest that 
the initial ZIP ancestor gene duplication event took place around the time when ZIP10 
sequences diverged from the lineage that gave rise to today’s ZIP518. At that time, 
sequence features of the ZIP10 PL domain which we found conserved in the globular 
domain of PrPC, had subtly diverged from those found in ZIP5 and ZIP6. Additionally, 
the extracellular N-terminal domain of this ZIP ancestor probably had not expanded 
beyond what is seen in today’s ZIP5. N-terminal tetra-repeat and octa-repeat sequences 
present in current Sho and PrP proteins, respectively, most likely emerged by expansion 
of a short sequence motif containing basic residues following their divergence from the 
ZIP transporter lineage. The emergence of extended histidine-rich repeat sequences 
within the N-terminal domain of ZIP10 and ZIP6 may have served a similar purpose in 
the functional specialization of these proteins (Fig. 3a). Interestingly, a strikingly similar 
histidine-rich repeat sequence with preferential zinc binding properties can also be found 
in zebrafish PrP30 (Supplementary Fig. 2). 
Whereas the genomic organization of genes encoding for proteins of the prion 
protein family has been subjected to close scrutiny previously31, relatively little is known 
about regulatory elements and the exon/intron structures of the slc39a gene family 
members. Our preliminary analysis revealed that a subset of slc39a10 ortholog genes 
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have in common with a subset of genes from the prion family the existence of a first exon 
containing non-coding regulatory sequence elements and a downstream exon in which a 
very short segment of non-coding sequence is followed by the respective ATG start 
codons. The protein coding region of all members of the prion protein family is confined 
to a single exon. ZIP proteins, in contrast, are encoded by multiple exons. In particular, 
exon/intron arrangements of ZIP gene sequences encoding for protein sequences 
upstream of the PL domain are most diverse and may be encoded by a single exon (e.g. 
mouse ZIP10) or multiple exons with non-conserved intron/exon boundaries across 
ortholog ZIP sequences. A more complete understanding of genomic rearrangements 
underlying the emergence of prion sequences from a ZIP ancestor gene will have to be 
based on a comparison of all aspects of the respective genomic segments in multiple 
organisms. 
DISCUSSION 
Taken together, the data presented here constitute conclusive evidence that the 
mammalian prion protein family evolved from a specific branch of a highly conserved 
family of ZIP metal ion transporters, possibly as a result of a phylogenetically ancient 
and partial gene duplication event. This origin places a ZIP5/ZIP10-like ancestor gene at 
the root of the PrP gene family. It explains the existence of prion genes in the vertebrate 
lineage, and explains structural and biological features within prion proteins as remnants 
of an ancient involvement in the sensing and/or import of metal ions present in the 
extracellular milieu. While it remains to be determined to what degree prion proteins 
have retained functional involvement in metal ion transport, the co-purification of ZIP 
proteins and prion protein family members documented here suggests an ability of these 
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proteins to inhabit the same subcellular space and to recognize each other has been 
conserved throughout evolution. 
The availability of genomic sequences from the teleost lineage proved highly 
useful for this work. The presence of multiple copies of prion genes in this vertebrate 
branch may have helped to preserve original ZIP-like features in a subset of these genes.  
A phylogenetic linkage of teleost and mammalian prion genes has been established 
earlier32 and therefore conclusions drawn from teleost sequence alignments are also 
relevant for establishing evolutionary relationships of mammalian prions. Because teleost 
prion related sequences diverged from the tetrapod lineage hundreds of millions of years 
ago — a time period during which they evolved independently — they should, however, 
not be considered precursors of prion sequences in the tetrapod lineage.  
Whereas PrPC is inserted into the membrane by the presence of a C-terminal 
glycosylphosphatidylinositol (GPI) anchor33, ZIP5 and ZIP10 are type III transmembrane 
proteins characterized by a relatively large N-terminal extracellular domain, 
encompassing about half of the molecule’s primary structure, and a C-terminal domain 
harboring up to eight transmembrane spanning segments (Fig. 3b). Evolutionary 
precedents exist in other protein families in which some members are inserted into the 
membrane through transmembrane domains while others employ a GPI anchor for 
membrane attachment. This dichotomy of membrane attachment modes has, for example, 
been documented among members of the carcinoembryonic antigen (CEA) protein 
family34 and cadherins, a diverse family of GPI-anchored (T-cadherin), single-spanning 
(classical cadherins and protocadherins) and multi-spanning (7TM-cadherins) 
transmembrane proteins35. In some instances surprisingly small changes in the protein 
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sequence within or in proximity to the first transmembrane domain have been shown to 
cause a shift to GPI anchor-based modes of membrane attachment36-38.  
The function of the extracellular PL domain within the ZIP family branch 
containing ZIPs 5, 6 and 10 has yet to be characterized. However, multiple more distantly 
related paralogs (ZIPs 4, 8, 12 and 14) contain a homologous domain and for ZIP4, a 
protein which has been genetically linked to a rare recessive zinc deficiency disorder 
(acrodermatitis enteropathica), a role of N-terminal sequences in the sensing of metal 
ions has recently been suggested39. Interestingly, upon depletion of extracellular zinc, 
ZIP4 has been shown to undergo endoproteolytic cleavage near its ‘PALLY’ motif, 
which in turn appears to lower the threshold for cellular zinc uptake39. 
This work holds promise for efforts to elucidate the physiological function of 
members of the prion protein family. It is hoped that a mechanistic understanding of the 
workings of ZIP transporters as well as high-resolution structures of their extracellular 
domains provide insights into the origins and constraints underlying conformational 
changes associated with prion diseases. Additional work will also be needed to reveal 
whether membrane-inserted ZIP transporters or N-terminal fragments thereof shed into 
the extracellular space play a direct role in the manifestation or propagation of prion 
disease. 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
09
.2
86
7.
1 
: P
os
te
d 
10
 F
eb
 2
00
9
  Page 17 
METHODS 
Molecular clones 
FLAG affinity tags were inserted before residue 29 of mouse PrP, residue 27 of mouse 
Dpl, and residue 26 of mouse Sho (all in the pcDNA3 mammalian expression vector) 
using standard PCR-based mutagenesis techniques. The identity of all constructs was 
verified by DNA sequencing.  
Cell culture 
Mouse neuroblastoma cells (N2a) were cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM) medium containing 10% fetal bovine serum (FBS) and 0.2 × 
penicillin/streptomycin and maintained in a humidified environment in the presence of 
5% CO2. N2a cells were either transiently or stably transfected with the FLAG-prion 
constructs or a native pcDNA3 vector (negative control) in OptiMEM using 
Lipofectamine 2000 (Invitrogen Canada, Burlington, ON, Canada) according to the 
manufacturer’s protocol. For bulk selection of stably transfected cells, cultures were 
expanded in the presence of 1 mg/mL G418 and maintained at a concentration of 0.2 
mg/mL G418.  
In vivo crosslinking 
Mild formaldehyde crosslinking of N2a cells followed a protocol described before 16. 
Briefly, cells grown to confluency were washed with phosphate buffered saline (PBS) 
and subjected to 15 min crosslinking with 2% w/v formaldehyde in PBS at room 
temperature. The crosslinking reaction was quenched by incubating cells for 15 min with 
125 mM glycine in PBS.  
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Affinity purification of bait proteins 
Approximately 108 in vivo formaldehyde crosslinked cells each of control and FLAG-
prion expressing N2a cell lines were lysed in homogenization buffer (50 mM NH4Cl, 80 
mM Tris, pH 8.0) supplemented with 1× Complete Protease Inhibitor Cocktail (Roche, 
Palo Alto, CA, USA). To ensure near quantitative extraction of membrane proteins, an 
equal volume of extraction buffer (20 mM NaCl, 1% deoxycholate, 1% NP-40, 20 mM 
Tris, pH 8.0) was added, followed by a 30-min incubation and 5-min sonication in a 
water bath sonicator. Insoluble cellular debris was removed by high-speed centrifugation 
(100,000 × g, 1 h). Subsequently, the crosslinked bait protein complexes were 
immunoaffinity-captured on anti-FLAG-agarose (Sigma-Aldrich, Oakville, ON, Canada). 
During this step samples were gently agitated on a turning wheel for 12 h, then washed 
extensively with 0.5 M NaCl, 0.05% SDS, 1% NP-40, 20 mM HEPES, pH 7.3, and 
detergents removed by a pre-elution wash with 10 mM NH4HCO3, pH 8.0. Proteins were 
eluted by acidification with 0.2% trifluoroacetic acid, 20% acetonitrile, pH 2.0. 
Protein reduction, alkylation and trypsinization 
Protein containing fractions were denatured in the presence of 6 M urea, 20 mM 
NH4HCO3, pH 8.0, followed by reduction with 1 mM Tris-(2-carboxyethyl)-phosphine 
for 30 min at 60°C and alkylation with 2.5 mM 4-vinylpyridine for 1 h at room 
temperature in the dark. Samples were diluted four-fold to ensure that the concentration 
of urea did not exceed 1.5 M. Tryptic digestion was initiated by the addition of 1% 
(wt/wt) of side chain-modified, TPCK-treated porcine trypsin and allowed to proceed at 
37°C for 6 h. 
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iTRAQ labeling  
Following trypsinization, equal quantities of tryptic peptide mixtures were spiked with 1 
pmol of synthetic (Glu1)-Fibrinopeptide B (GluFib) (Sigma-Aldrich) to serve in the 
downstream analysis as an internal control for the efficiency of individual labeling 
reactions. Equal labeling with all four reagents was confirmed by equal intensities of 
114:115:116:117 signature peaks upon forced fragmentation of the GluFib [M+2H]2+ 
parent ion at m/z 785.85 . Any strong deviation from this ratio would have indicated 
problems with the labeling reaction or recovery of individual samples prior to the sample 
mixing step. Individual iTRAQ labeling reagents (Applied Biosystems, Foster City, CA, 
USA) were reconstituted in ethanol, added to peptide mixtures derived from the tryptic 
digestion of IP eluates (Control: iTRAQ 114, Dpl: iTRAQ 115, PrP: iTRAQ 116 , Sho: 
iTRAQ 117) and incubated at room temperature in the dark for 3 h.  
Two-dimensional liquid chromatography 
Strong cation exchange (SCX) chromatography was used to achieve peptide fractionation 
of the complex digest mixture. Samples digested with trypsin were adjusted to 25% 
acetonitrile and acidified (pH 3.0) by 20-fold dilution in 25% acetonitrile, 20 mM 
KH2PO4, pH 3.0. HPLC was carried out using the Ultimate System (Dionex, Sunnyvale, 
CA, USA) equipped with a microflow calibration cartridge, a Valco injection port and a 
180 nL volume UV cell. Separation was achieved on a self-packed 0.5 mm × 110 mm 
Luna SCX (Phenomenex, Torrance, CA, USA) column at a flow rate of 18 µl/min with a 
steep salt gradient from 0–400 mM NH4Cl in 25% acetonitrile, 20 mM KH2PO4, pH 3.0. 
Fractions eluted from the SCX column were desalted with C18 Empore (3M, 
Minneapolis, MN, USA) stop and go extraction (STAGE) tips40 and subsequently 
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subjected to nano-flow RP-HPLC using the Ultimate LC system (Dionex) equipped with 
a nanoflow calibration cartridge at a flow rate of 250 nL/min. Peptides were separated on 
a 75-µm ID self-packed column containing Proteo C12 reverse-phase matrix 
(Phenomenex) using a 100-min gradient from 2%–34% acetonitrile in water, with 0.1% 
(wt/vol) formic acid as the ion-pairing agent. 
ESI-QqTOF mass spectrometry analysis 
The column effluent was coupled directly via a fused silica capillary transfer line to a 
QSTAR XL hybrid quadrupole/time-of-flight tandem mass spectrometer (Applied 
Biosystems; MDS Sciex, Concord, ON, Canada) equipped with a MicroIonSpray source. 
The progress of each LC/MS run was monitored by recording the total ion current (TIC) 
as a function of time for ions in the m/z range 300 to 1800. At 5-s intervals through the 
gradient, a mass spectrum was acquired for 1 s, followed by one collision-induced 
dissociation (CID) acquisition of 4 s each on ions selected by preset parameters of the 
information-dependent acquisition (IDA) method, using nitrogen as the collision gas. 
Singly-charged ions were excluded from CID selection. The collision energy was 
adjusted automatically for each CID spectrum using an empirically optimized formula 
which considers the charge state and m/z value of the precursor ion. 
Database searches 
Peak lists for database searching were created using Mascot Distiller (Version 1; 
MatrixScience, London, UK). Searches were performed using designated MS/MS data 
interpretation algorithms within Protein Prospector (Version 4.21.3; University of 
California, San Francisco, CA, USA)41 and Mascot (Version 2.2; MatrixScience). 
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Modifications considered were oxidation of methionine, phosphorylations of serine and 
threonine, N-terminal (pyro)Glu and alkylation with 4-vinylpyridine. Searches further 
considered up to one missed cleavage and charge states ranging from +2 to +4. For a 
protein to be listed in the data tables it had to be identified by both search algorithms. In 
the few instances where only two peptides supported the identification of a protein, we 
required the underlying CID spectra to generate a Mascot score indicating a <5% 
probability that the match could be considered a random event42 and further confirmed 
matches by the peptide sequence tag approach43 and manual interpretation of spectra. As 
searches were carried out without species restriction, the correct assignment of matches 
to mouse entries served as an additional internal control. The mass tolerance range 
between expected and observed masses used for database searches was ±150 ppm for MS 
peaks, and ±0.15 Da for MS/MS fragment ions. These relatively large thresholds were 
used to capture more of the low intense peaks that frequently display broader distribution 
and thus are assigned with lower mass accuracy. Threshold levels were optimized based 
on LC/MS/MS datasets of tryptic digests of standard proteins. All samples were searched 
against the National Center for Biotechnology Information nonredundant database 
(nrNCBI, release: June 2008) and a ‘decoy’ database in which all entries of the above 
NCBI database had been inverted. The analysis of iTRAQ data was assisted by the 
software program ProteinPilot (Applied Biosystems; MDS Sciex). A feature of this 
software package was used to correct raw iTRAQ ratios for impurity levels of individual 
reagent lots determined by the manufacturer.  
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Western blotting 
Cells were lysed in 0.5% sodium deoxycholate, 1% NP-40, 150 mM NaCl, 50 mM 
Tris/HCl, pH 8.0 and extracts clarified by centrifugation at 20,000 × g for 10 min at 4°C. 
Protein concentrations were determined using the bicinchoninic acid assay (BCA) (Pierce 
Biotechnology, Rockford, IL, USA). Proteins were separated on 4-12% NuPAGE gels 
(Invitrogen) and subsequently transferred to polyvinylidene fluoride (PVDF) membranes. 
Membranes were blocked with 5% milk in Tris-buffered saline containing 0.05% Tween-
20 (TBST). Membranes were incubated overnight at 4°C with primary antibody, washed 
three times with TBST, and incubated with horseradish peroxidase-conjugated secondary 
antibody (Bio-Rad Laboratories, Hercules, CA, USA) for 2 h at room temperature. 
Following three washes with TBST, membranes were developed using Western 
Lightning ECL (PerkinElmer, Woodbridge, ON, Canada).  
Multiple sequence alignments 
Multiple sequence alignments were obtained using a combination of MAFFT44 and 
ClustalX2’s implementation of ClustalW245. Small manual adjustments were made to 
further improve alignments. Sequence identity and conservation were calculated using 
the AlignX feature of Vector NTI Advance 10.3.1 (Invitrogen, Carlsbad, CA, USA)46. To 
determine the statistical significance of alignments, the COMPASS program was used22. 
Analyses were based on the ‘SCOP40 iter5’ database, GAP opening and extension 
penalties of 10 and 1, respectively, and the BLOSUM62 substitution matrix.   
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Accession numbers 
The following sequences were retrieved from GenBank: M. musculus PrP 
(NP_035300.1), M. musculus Sho (CAF18554.1), M. musculus Dpl (AAF02544.1), M. 
musculus ZIP5 (AAH28990.1), G. aculeatus PrP-1 (CAL64057.1), T. rubripes PrP 
(AAN38988.1), T. rubripes Sho1 (CAG34291.1), T. rubripes Sho2 (CAG34292.1), D. 
rerio PrP (NP_991149.1), D. rerio ZIP10 (NP_956965.1) and D. rerio ZIP5 
(XP_690258.2). Sequences for M. musculus ZIP10 (ENSMUSP00000027131), G. gallus 
PrP (ENSGALP00000040285), G. gallus ZIP10 (ENSGALP00000012604), X. tropicalis 
PrP (ENSXETP00000036722), X. tropicalis ZIP10 (ENSXETP00000040857), G. 
aculeatus ZIP10 (ENSGACG00000002320) and T. rubripes ZIP10 
(ENSTRUP00000007404) were retrieved from Ensembl. 
Structural threading 
The sequence of the PL domain of ZIP10 was submitted to the FFAS03 fold and function 
assignment server23 for structure prediction and structural threading. In order to eliminate 
threading artifacts based on uncertainties in determining the boundaries of the PL 
domain, we submitted a number of alternatively truncated sequences to the FFAS03 
server. This approach helped to better define the boundaries of the folded region of the 
PL domain of ZIP10. The FFAS03 server provided a ranked list of structural threading 
models based on various Protein Data Bank (PDB) entries; invariably the highest scoring 
models were based on PrP47 and Dpl48 structures. We analyzed all sensible models for the 
position of secondary structure elements and derived a consensus prediction for the 
secondary structure of the PL domain of ZIP10. The closest model to the consensus 
prediction was chosen for the corresponding figure. 
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FIGURE LEGENDS 
Figure 1: Structural similarity between mouse ZIP10, PrP and Dpl. a, Structural 
threading of the PL domain within ZIP10 predicts striking resemblance to PrP and Dpl 
with regard to relative position and order of secondary structure motifs. The secondary 
structure for the PL domain of ZIP10 was ranked according to the frequency of the 
prediction in separate threadings (H 75-100%, H 50-75%, h 25-50%, h 0-25% for α-
helices; the same scale applies to β-sheeted structures “E/E/e/e”). b, Comparison of high-
resolution nuclear magnetic resonance structures of PrP and Dpl with a predicted 
structure for the ZIP10 PL domain. Dark green, grey and black highlights depict 
conserved, similar and identical residues, respectively. ‘S’ and ‘G’ labels indicate sites of 
disulfide linkages and glycosylation, respectively. 
Figure 2: Sequence evidence for common origin and divergent sequence evolution of 
members of ZIP and prion protein families. a, Multiple sequence alignment of PrP 
globular domain with ZIP10 PL domain from pufferfish and mouse. b, Multiple sequence 
alignment of N-terminal Sho and ZIP5 sequences from pufferfish, zebrafish and mouse. 
The addition of murine sequences served to document the greater divergence of 
orthologous proteins in mouse. Highlight colors are as in Figure 1. ‘N’, ‘S’, ‘G’ and ‘C’ 
labels indicate N-termini, disulfide linkages, glycosylation sites and C-termini, 
respectively. For full-length multiple alignments of these and related sequences, please 
see Supplementary Fig. 2. 
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Figure 3: Models depicting evolutionary origin and topology of members of prion 
protein family, hypothetical ZIP ancestor and ZIP10 transporter. a, Cartoon 
depicting the emergence of members of the prion gene family from ZIP ancestor gene(s): 
(i) Hypothetical Sho ancestor gene, (ii) prion gene founder and (iii) evolutionary 
intermediate prion gene family ancestor. Alternative hypotheses for the origin of prion 
genes: (1) insertion of ZIP ancestor-derived PL domain into Sho ancestor molecule; or 
(2) duplication of N-terminal ZIP ancestor fragment followed by expansion of 
hydrophobic domain and differentiation of former transmembrane domain into signal 
peptide for attachment of GPI anchor. Based on the above models, Sho genes (1) either 
evolved independently or (2) are themselves derived from a ZIP ancestor. Please note that 
our analyses strongly favor model (2). b, Comparison of orientation and membrane 
topology of prion proteins, hypothetical ZIP ancestor protein and today’s ZIP10.  
Supplementary Figure 1: Evidence for specific co-enrichment of ZIP10 and ZIP6 
with all three members of the mammalian prion protein family. Comparison of 
FLAG-affinity chromatography eluates by quantitative tandem mass spectrometry. Side-
by-side affinity purified bait protein complexes were trypsinized and subjected to iTRAQ 
labeling of peptides as follows: iTRAQ114 label: empty vector; iTRAQ115 label: FLAG-
Dpl; iTRAQ116 label: FLAG-PrP; and iTRAQ117 label: FLAG-Sho. a, ZIP10 co-
purified specifically with the three bait proteins. Collision induced dissociation (CID) 
spectrum from ZIP10 derived peptide with amino acid sequence QSTEEIGR ([M+2H]2+, 
m/z 626.35). Inset: Low mass iTRAQ reporter ion region documenting relative 
contribution to the identification of this peptide by samples labeled with iTRAQ115 
(FLAG-Dpl), iTRAQ116 (FLAG-PrP) and iTRAQ117 (FLAG-Sho) reagents but not 
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negative control sample labeled with iTRAQ114 reagent. b, CID spectrum derived from 
ZIP6 peptide with amino acid sequence ESASSSEVTSAVYNAVSEGTR ([M+3H]3+, 
m/z 759.03). iTRAQ reporter ions document that ZIP6 co-purified specifically with the 
three bait proteins. c, Actin co-purified unspecifically in all four samples including the 
negative control. CID spectrum derived from actin peptide with amino acid sequence 
TTGIVMDSGDGVTHTVPIQEGYALPHAILR ([M+4H]4+, m/z 666.35). 
Supplementary Figure 2: Multiple full-length sequence alignment of selected 
mammalian and teleost ZIP and prion gene sequences. Due to the presence of large 
insertions found in a subset of depicted sequences, this alignment required extensive 
manual curation. Amino acid-specific colours were employed to facilitate visual 
comparison of sequences. 
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Table 1: Quantitative analysis of mouse Dpl, PrP and Sho interactomes identifies metal ion transporters of the ZIP protein family in spatial  
                 proximity to all three members of the mammalian prion protein family       
     IPs & iTRAQb 
  Identified proteinsa IPI accession  
number 
Amino    
acidsc 
Peptidesd Uniquee % Covf 114 
Control 
115 
Dpl 
116 
PrP  
117 
Sho 
Specific binders           
Dpl IPI00131622.1 178 8 13 39.1 2.0 92.5 3.0 2.5 
PrP   IPI00120793.1 254 5 5 26.8 4.0 20.5 65.1 10.5 
Sho IPI00226455.1 147 3 6 50.4 2.9 11.4 20.5 65.2 
ZIP10 IPI00273801.3 833 2 2 4.3 2.4 36.3 16.7 44.6 
ZIP6 IPI00469000.4 765 3 3 7.3 3.2 29.9 32.8 34.2 
Unspecific binders           
Actin IPI00110850.1 375 21 46 88.5 19.1 21.6 31.8 27.5 
aProteins were sorted into specific versus unspecific binder categories based on their iTRAQ distribution, i.e. proteins were considered unspecific interactors if their 
derived CID spectra revealed iTRAQ114 to 117 signature mass peak signal intensities which exceeded 10% of combined intensities for all samples including the 
unspecific control. 
bFor the calculation of iTRAQ values the intensity of individual peptide associated iTRAQ signature peaks was normalized to combine to 100% per peptide and 
subsequently averaged. Standard deviations were determined and are listed in Supplementary Table 1. 
 cLength of precursor molecules prior to posttranslational processing. 
 dOnly CID spectra underlying different peptides were considered i.e. if the same peptide was identified with different charge states or modifications it counted as one hit. 
eTotal number of unique CID spectra. Please note that the same peptide was only counted more than once if it was identified with different charge states or modifications. 
fPercent sequence coverage based on the presence of peptides for which no higher ranked assignment to other proteins could be made.  
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Figure 1 
 
 
a               
 
                  ---+---------+---------+---------+---------+---------+--S-G----+---------+----G----+---------+-S-------+--------- 
Mm_PrP       124  LGGYMLGSAMSRPMIH-FGNDWEDRYYRENMYRYPNQVYYRP-VDQYSNQNNFVHDCVNITIKQHTVTTTTKG----ENFTETDVKMMERVVEQMCVTQYQKESQAYYDGRRS  230 
Mm_Dpl        56  RPGAFIKQG-RKLDID-FGAE-GNRYYAANYWQFPDGIYYEGCSEANVTKEMLVTSCVNATQAANQAEFSREK-----QDSKLHQRVLWRLIKEICSAKHCDFWLERGAA---  157 
Mm_ZIP10     285  HSGHELGHGHQELDPDNEGELRHTR-KREAPHVRKSAIYSTP-SHKDQSEDDRQHECLNVTQLLKHFGLGPNSPISPDLFTYLCPALLYQIDSRLCIEHFDKLLVEDLNKDKT  395 
Mm_PrP 2D            EEEE             HHHHHHHHHHH      EEEE               HHHHHHHHHHHHHHH          HHHHHHHHHHHHHHHHHHHH 
Mm_Dpl 2D            EEE             HHHHHHHHHHH     EEE          HHHHHHHHHHHHHHHHHHHHHHHHH        HHHHHHHHHHHHHHHHH 
Mm_ZIP10             eEEEee      hhhhHHHHHHHHHHhhhh  eeEEe         HHHHHHHHHHHHHHHHhhhhhhhhhhhhhh  HHHHHHHHHHHHHHHHHHHHHHh 
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                                          PrP                                                               Dpl                                                               ZIP10 PL domain 
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Figure 2 
 
 
a                      
 
        ---------+----S-G--+---------+-------G-+---------+----S----+---------+---------+---------+---------+---------+-C 
Mm_PrP    164  PVDQYSNQNNFVHDCVNITIKQHTVTTTTKG-----ENFTETDVKMMERVVEQMCVTQYQKESQAYYDGRRSSS------------TVLFSSPPVILLISFLIFLIVG----  255 
Tr_PrP   352  PPPRAESYENFMDRCMNRTDLLKDKGGKTDGDDDTVGIEEIGYPALVDQMKSRRCVEEYMAYSEQ-FLEKQARN------------RCGPLSFGAIQLFSSLLLLSSTLLLQ  451 
Tr_ZIP10  387  PGAHQGEVAHQHEECLNLTQLLQYYGLNPD-SPISPSQFTYLCPALLYQIDSRVCIQHDHQMVEQEPLEPLSTV---------WVWLWGFVSITIISLLSLLGVVLVPFLKQ  489 
Mm_ZIP10  325  PSHKDQSEDDRQHECLNVTQLLKHFGLGPN-SPISPDLFTYLCPALLYQIDSRLCIEHFDKLLVEDLNKDKTLVPEDKTNIGASAWICGIISITVISLLSLLGVILVPIINQ  436 
                                                              ----- 
                       PALLY                   
 
b  
 
        N--G-----+---------+---------+---------+---------+---------+---------+-------G-+---------+---------+---------+-- 
Mm_Sho      1  --MNWTAATCWALLLAAAFLCDSCSAKGGRGGARGSARGVRGGARGASRVRVRP-------APRYGSSLRVAAAGAAAGAAAGVAAGLATGS-GW-R------RTSGPGELG  95 
Tr_Sho2    1  MTGQQKLLSLWVWLLLMAALCPGVQHAY---GKRGGVFKGRGKGDSTQAAPSQ--------GRGLPKPGLKWA-GAAAGILGGTGTGYGLGFLGR-------HKHGSGGHHS  93 
Dr_ZIP5    1  MGGQTVWMTLSFKLLLYYCMISLLMPAIFILATRAQVDKFRKFNESTQTKSSQELFEEAFEEQGYYLQRLFLQYG-DNGTLTYEGLQKLLGSLGLGEVSVLEIRHGEAKHPS  111 
Mm_ZIP5    1  -------------------MGPPV-HHLLTGLCVGVALGWVGGSVPNLGPAEQE--------QNHYLAQLFGLYG-ENGTLTAGGLARLLHSLGLGRVQ--GLRLGHHEPPT  81 
                                                   ----------                                -----------------------     ----------  
                                                Basic motif                                  Hydrophobic segment       Histidine 
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Mm_PrP 1——        M  A  N  L  G  Y  W  L  L  A  L  F  V  T  M  W  T  D  V  G  L  C  -  -  -  -  -  K  K  R  P  K  P  G  G  W  N  T  G  G  S  R  Y  P  G  Q  G  S  P  G  G  N  R  Y  P  P  Q  G  G  T  W  G  Q  P  H  G  G  G  W  G  Q  P  H  G  G  S  W  G  Q  P  H  G  G  S  W  G  Q  P  H  G  G  G  W  G  Q  G  G  G  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  T  H  N  Q  W  N  K  P  S  K  P  K  T  N  L  K  H  V  A  G  A  A  A  A  G  A  V  V  G  G  L  G  G  Y  M  L  G  S  A  M  S  R  P  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  M  I  H  -  F  G  N  D  W  E  D  R  Y  Y  R  E  N  M  Y  R  Y  P  N  Q  V  Y  Y  R  P  V  D  Q  Y  S  N  Q  N  N  F  V  H  D  C  V  N  I  T  I  K  Q  H  T  V  T  T  T  T  K  G  -  -  -  -  -  E  N  F  T  E  T  D  V  K  M  M  E  R  V  V  E  Q  M  C  V  T  Q  Y  Q  K  E  S  Q  A  Y  Y  D  G  R  R  S  S  S  -  -  -  -  -  -  -  -  -  -  -  -  T  V  L  F  S  S  P  P  V  I  L  L  I  S  F  L  I  F  L  I  V  G  -  -  -  -  -  -  -  -  -      ——255 
Tr_PrP 1——        -  M  G  R  L  C  E  V  V  L  L  S  L  -  L  L  L  F  L  L  N  T  K  A  T  W  A  K  K  S  G  S  S  G  G  K  K  T  G  S  S  T  N  W  G  S  R  T  P  S  K  P  S  G  S  Q  P  N  R  N  S  N  P  Y  P  S  G  G  S  Y  P  H  P  G  T  G  Q  S  N  P  G  G  Y  P  R  Q  N  P  A  S  N  P  V  G  G  S  P  N  Q  Y  P  G  R  T  N  P  G  G  Y  P  N  Q  N  P  A  G  G  G  Y  P  N  Q  N  P  A  R  G  N  Y  P  N  Q  Y  P  A  G  G  S  N  P  N  Q  Y  P  G  R  A  G  T  N  Q  G  G  Y  P  N  Q  Y  P  P  A  G  G  Y  P  G  Q  G  G  Y  P  A  A  G  R  Y  P  G  Q  G  G  Y  P  Q  Y  P  A  A  G  G  Y  P  N  Q  R  S  P  Y  Q  Y  P  A  A  G  G  Y  P  V  R  T  G  N  T  G  P  G  W  G  Q  P  G  G  H  P  G  G  Y  P  G  G  Y  P  G  G  Y  P  G  G  A  V  G  G  Y  T  N  W  N  P  N  N  K  I  L  S  P  R  F  G  G  G  G  Y  M  P  G  M  G  G  S  P  F  S  Q  S  V  Q  S  M  G  Y  -  K  P  K  S  P  -  S  F  A  K  K  A  M  V  A  A  G  V  G  A  V  A  G  M  A  V  G  Y  G  L  G  -  R  F  P  R  P  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  H  F  G  F  R  S  P  S  E  E  Y  Y  Y  N  N  Y  M  Y  H  R  Y  G  T  Q  S  T  D  E  K  D  Y  G  R  D  Y  V  Y  K  P  P  P  R  A  E  S  Y  E  N  F  M  D  R  C  M  N  R  T  D  L  L  K  D  K  G  G  K  T  D  G  D  D  D  T  V  G  I  E  E  I  G  Y  P  A  L  V  D  Q  M  K  S  R  R  C  V  E  E  Y  M  A  Y  S  E  Q  -  F  L  E  K  Q  A  R  N  -  -  -  -  -  -  -  -  -  -  -  -  R  C  G  P  L  S  F  G  A  I  Q  L  F  S  S  L  L  L  L  S  S  T  L  L  L  Q  -  -  -  -  -      ——451 
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Dr_ZIP10 475——      L  L  T  F  L  V  A  L  A  V  G  T  L  S  G  D  A  L  L  H  L  L  P  H  S  Q  G  D  H  D  H  N  H  G  E  Q  M  E  E  E  P  E  V  -  -  -  -  -  D  F  L  I  K  F  D  G  V  W  K  G  L  T  A  L  A  G  I  Y  L  L  F  I  I  E  H  C  I  G  M  F  K  H  Y  S  D  Q  R  G  G  L  C  H  K  K  K  K  G  E  Q  A  K  I  G  R  K  L  S  D  H  K  L  N  R  R  S  D  A  E  W  L  H  L  K  P  L  T  -  -  -  E  G  D  G  T  T  C  E  A  G  H  N  D  T  Q  M  T  E  L  Q  P  L  D  S  P  S  K  M  P  L  N  I  S  D  S  D  H  P  Y  E  A  P  V  K  T  E  E  D  N  V  P  K  A  K  S  K  K  H  G  -  -  -  -  -  -  -  -  -  -  -  -  -  -  H  G  H  G  H  G  H  G  H  G  H  G  H  S  H  H  G  H  C  H  S  D  Q  E  M  K  D  A  G  I  A  S  I  A  W  M  V  I  M  G  D  G  M  H  N  F  S  D  G  L  A  I  G  A  A  F  S  A  N  I  T  G  G  I  S  T  S  V  A  V  F  C  H  E  L  P  H  E  L  G  D  F  A  V  L  L  K  A  G  M  S  V  K  Q  A  I  V  Y  N  L  L  S  A  L  M  A  Y  A  G  M  V  I  G  T  A  V  G  Q  Y  T  H  N  V  T  S  W  I  F  A  V  T  A  G  M  F  L  Y  V  A  L  V  D  M  L  P  E  M  L  H  G  D  S  E  E  H  K  R  -  -  C  E  M  G  H  F  V  L  Q  N  F  G  M  L  T  G  F  G  I  M  L  L  I  A  I  F  E  D  H  I  V  L  D  F  G  F  -  -  -  -  -  -      ——847 
Mm_ZIP5 243——      V  L  G  F  L  G  A  L  A  V  G  T  L  C  G  D  A  L  L  H  L  L  P  H  A  Q  G  G  R  H  T  G  P  S  E  Q  S  E  E  D  L  G  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  P  G  L  S  V  L  G  G  L  F  L  L  F  M  L  E  N  T  L  G  L  V  R  H  R  G  L  R  P  R  -  -  -  -  C  C  R  N  K  R  D  L  G  E  P  N  P  -  D  P  E  D  G  S  G  M  V  L  R  P  L  Q  A  A  S  E  P  E  V  Q  G  Q  R  E  N  R  Q  S  S  P  S  L  A  P  P  G  H  Q  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  G  H  S  H  E  H  R  -  -  -  -  -  -  -  -  -  -  -  G  G  S  I  A  W  M  V  L  L  G  D  C  L  H  N  L  T  D  G  L  A  L  G  A  A  F  S  D  G  F  S  S  G  L  S  T  T  L  A  V  F  C  H  E  L  P  H  E  L  G  D  F  A  M  L  L  Q  E  G  L  S  F  R  K  L  L  L  L  S  L  V  S  G  A  L  G  L  G  G  A  A  L  G  V  G  L  S  L  G  P  V  P  L  T  P  W  V  F  G  T  T  A  G  V  F  L  Y  V  A  L  V  D  M  L  P  T  L  L  R  P  P  E  P  L  -  -  -  -  -  -  P  V  F  H  V  L  L  Q  G  L  G  L  L  L  G  G  S  L  M  F  T  I  A  L  L  E  E  Q  L  V  P  T  V  P  D  G  -  -  -  -  -      ——535 
Dr_ZIP5 279——      F  L  C  P  M  A  G  M  A  V  G  T  L  C  G  D  A  L  L  H  L  M  P  H  A  I  F  S  Q  H  T  D  H  Q  N  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  A  V  F  K  G  L  S  V  L  G  G  L  Y  L  L  F  I  F  E  S  L  L  G  L  K  Q  H  F  K  N  L  K  R  -  -  -  -  R  K  H  D  A  E  C  G  R  E  L  D  A  L  Q  G  T  S  S  A  N  Q  N  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  E  S  S  G  H  G  H  S  H  G  Q  -  -  -  -  -  A  E  P  G  Q  T  G  I  R  S  M  A  W  M  V  V  M  G  D  G  I  H  N  L  T  D  G  L  A  I  G  V  A  F  S  Q  S  L  T  G  G  F  S  T  A  I  A  V  F  C  H  E  L  P  H  E  L  G  D  L  A  V  L  L  S  A  G  W  P  V  R  R  L  L  V  F  S  G  L  S  A  L  L  G  F  V  G  V  L  A  G  S  A  L  G  N  H  W  A  S  H  S  P  W  I  L  T  L  T  A  G  V  F  L  Y  V  A  L  A  D  M  M  P  E  M  L  H  G  A  C  G  S  V  S  -  -  -  -  P  L  K  R  F  L  L  Q  A  L  G  L  L  T  G  G  A  I  M  L  C  I  A  L  F  E  D  H  I  A  V  S  L  G  E  N  S  L  G  E  N      ——555 
Tr_Sho2            -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
Mm_Sho            -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
Tr_Sho1            -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
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Accession number Symbol Protein Conf Sequence Modifications Cleavages dMass Prec MW Prec m/z Theor MW Theor m/z Theor z Area 114 Area 115 Area 116 Area 117
IPI:IPI00131622.1 DPL doppel 99 HCDFWLER iTRAQ4plex@N-term; Pyridylethyl(C)@2 -0.03 1353.61 452.21 1353.64 452.22 3 6.0 89.0 3.4 1.6
99 VAENRPGAF iTRAQ4plex@N-term cleaved F-I@C-term 0.00 1103.58 552.80 1103.58 552.80 2 0.7 94.7 1.7 2.9
99 VLPSSGGQITEAR iTRAQ4plex@N-term -0.01 1457.79 729.90 1457.80 729.91 2 0.1 98.1 1.2 0.6
99 LDIDFGAEGNR iTRAQ4plex@N-term -0.02 1349.65 675.83 1349.67 675.84 2 1.3 94.3 2.6 1.7
99 VLPSSGGQITEAR iTRAQ4plex@N-term; Ala->Val@12 0.01 1485.84 496.29 1485.83 496.28 3 1.6 89.9 2.4 6.0
99 VLPSSGGQITEARVAENRPGAFIKQGR iTRAQ4plex@N-term; Asn->His@17; Lys->Glu@24 missed R-V@13; missed K-Q@24 0.00 3005.59 752.41 3005.59 752.41 4 3.9 89.9 4.1 2.1
99 VLPSSGGQITEAR iTRAQ4plex@N-term; Deamidated(Q)@8; Dimethyl(R)@13 0.06 1486.87 496.63 1486.81 496.61 3 1.0 91.2 4.4 3.3
99 KVLPSSGGQITEAR iTRAQ4plex@N-term; iTRAQ4plex(K)@1 missed K-V@1 -0.02 1729.97 577.66 1729.99 577.67 3 1.7 91.0 4.1 3.2
99 KLDIDFGAEGNR iTRAQ4plex@N-term; iTRAQ4plex(K)@1 missed K-L@1 -0.04 1621.83 541.62 1621.87 541.63 3 2.4 87.6 6.3 3.7
99 KVLPSSGGQITEAR iTRAQ4plex@N-term; iTRAQ4plex(K)@1; HexNAc(T)@11 missed K-V@1 0.02 1933.09 645.37 1933.07 645.36 3 2.5 92.2 3.3 2.0
99 VAENRPGAFIK iTRAQ4plex@N-term; iTRAQ4plex(K)@11 0.96 1489.83 497.62 1488.87 497.30 3 0.0 99.4 0.0 0.6
99 VAENRPGAFIK iTRAQ4plex@N-term; Lys->Arg@11 -0.05 1372.72 687.37 1372.77 687.39 2 1.0 95.9 1.5 1.6
92 KVLPSSGGQITEAR iTRAQ4plex@N-term; Lys->Gln@1 missed K-V@1 0.05 1585.90 529.64 1585.85 529.63 3 3.5 89.0 3.8 3.7
Average: 2.0 92.5 3.0 2.5
StDev: 1.7 3.7 1.6 1.5
IPI:IPI00120793.1 PRNP prion protein 99 HVAGAAAAGAVVGGLGGYMLGSAMSR iTRAQ4plex@N-term cleaved R-P@C-term 0.03 2474.29 825.77 2474.26 825.76 3 7.0 25.9 55.7 11.5
96 QHTVTTTTK Gln->pyro-Glu@N-term; iTRAQ4plex(K)@9 0.02 1142.62 572.32 1142.61 572.31 2 2.2 24.0 61.0 12.8
99 PMIHFGNDWEDR iTRAQ4plex@N-term cleaved R-P@N-term 0.06 1659.82 554.28 1659.76 554.26 3 6.1 26.8 55.3 11.8
97 ESQAYYDGR iTRAQ4plex@N-term 0.00 1231.56 616.79 1231.56 616.79 2 3.4 11.5 76.4 8.6
99 VVEQMCVTQYQK iTRAQ4plex@N-term; Pyridylethyl(C)@6; iTRAQ4plex(K)@12 -0.09 1847.86 616.96 1847.95 616.99 3 1.1 14.2 76.9 7.7
Average: 4.0 20.5 65.1 10.5
StDev: 2.5 7.1 10.8 2.2
IPI:IPI00226455.1 SPRN shadoo 99 ICLLLGGTLGALELLRP iTRAQ4plex@N-term; Pyridylethyl(C)@2 -0.01 2000.19 667.74 2000.20 667.74 3 0.0 6.9 32.4 60.7
99 VAAAGAAAGAAAGVAAGLATGSGWR iTRAQ4plex@N-term -0.04 2198.13 733.72 2198.17 733.73 3 0.0 21.6 18.3 60.1
98 YGSSLR iTRAQ4plex@N-term 0.00 825.45 413.73 825.45 413.73 2 0.8 2.3 23.2 73.8
99 VAAAGAAAGAAAGVAAGLATGSGWR iTRAQ4plex@N-term; Oxidation(W)@24 -0.01 2214.15 739.06 2214.16 739.06 3 8.0 13.4 15.0 63.5
99 VAAAGAAAGAAAGVAAGLATGSGWR iTRAQ4plex@N-term; Val->Asn@14 0.05 2213.19 738.74 2213.14 738.72 3 7.1 12.9 15.4 64.7
99 VAAAGAAAGAAAGVAAGLATGSGWR iTRAQ4plex@N-term; Val->Met@14 0.07 2230.21 744.41 2230.14 744.39 3 1.4 11.1 18.8 68.7
Average: 2.9 11.4 20.5 65.2
StDev: 3.7 6.5 6.5 5.2
IPI:IPI00469000.4 SLC39A6 ZIP6 99 ESASSSEVTSAVYNAVSEGTR iTRAQ4plex@N-term 0.01 2274.08 759.03 2274.07 759.03 3 3.7 29.2 35.9 31.2
95 AGMTVK iTRAQ4plex@N-term; Dehydrated(T)@4; iTRAQ4plex(K)@6 -0.03 875.48 438.75 875.51 438.76 2 2.2 31.1 31.9 34.8
99 YDSQLSSNEEK iTRAQ4plex@N-term; Lys->Gln@11 0.06 1442.69 722.35 1442.63 722.32 2 3.7 29.2 30.5 36.6
Average: 3.2 29.9 32.8 34.2
StDev: 0.8 1.1 2.8 2.8
IPI:IPI00273801.3 SLC39A10 ZIP10 99 QSTEESTIGR iTRAQ4plex@N-term 0.03 1250.65 626.33 1250.62 626.32 2 2.3 39.3 15.7 42.7
98 NYLGVEEEK iTRAQ4plex@N-term; Lys->Gln@9 0.07 1223.65 612.83 1223.58 612.80 2 2.5 33.2 17.7 46.5
Average: 2.4 36.3 16.7 44.6
StDev: 0.2 4.3 1.4 2.7
IPI:IPI00110850.1 ACTB actin 99 AGFAGDDAPR iTRAQ4plex@N-term 0.02 1119.56 560.79 1119.54 560.78 2 27.5 13.1 37.0 22.4
99 AVFPSIVGR iTRAQ4plex@N-term cleaved R-P@C-term -0.02 1088.63 545.32 1088.65 545.33 2 27.2 13.0 27.9 31.9
99 AVFPSIVGRPR iTRAQ4plex@N-term -0.01 1341.79 448.27 1341.80 448.27 3 24.9 19.8 33.3 22.0
99 AVFPSIVGRPR iTRAQ4plex@N-term; Deamidated(R)@9 -0.03 1342.76 448.59 1342.78 448.60 3 25.5 14.2 33.8 26.5
84 AVFPSIVGRPR iTRAQ4plex@N-term; Dimethyl(R)@11 0.01 1369.85 457.62 1369.83 457.62 3 28.8 16.8 32.9 21.5
99 DLTDYLMK iTRAQ4plex@N-term; iTRAQ4plex(K)@8 0.00 1285.68 643.85 1285.68 643.85 2 18.2 23.6 37.5 20.7
98 DLTDYLMK iTRAQ4plex@N-term; Lys->Gln@8 0.02 1141.57 571.79 1141.54 571.78 2 10.6 8.5 30.5 50.4
99 DLYANTVLSGGTTMYPGIADR iTRAQ4plex@N-term 0.13 2358.29 787.10 2358.16 787.06 3 11.0 29.3 30.3 29.4
99 DLYANTVLSGGTTMYPGIADR iTRAQ4plex@N-term; Dimethyl(R)@21 0.03 2386.23 796.42 2386.20 796.41 3 30.1 18.6 0.0 51.3
99 DLYANTVLSGGTTMYPGIADR iTRAQ4plex@N-term; Leu->Pro@2 -0.02 2342.12 781.71 2342.13 781.72 3 5.7 28.2 29.4 36.7
99 DSYVGDEAQSK iTRAQ4plex@N-term; Dehydrated(S)@2; Lys->Gln@11 0.04 1323.61 662.81 1323.57 662.79 2 29.3 8.9 29.6 32.2
99 DSYVGDEAQSK iTRAQ4plex@N-term; iTRAQ4plex(K)@11 0.04 1485.76 496.26 1485.72 496.25 3 22.5 29.7 31.8 16.0
99 DSYVGDEAQSK iTRAQ4plex@N-term; Lys->Arg@11 0.04 1369.67 685.84 1369.62 685.82 2 21.7 10.8 31.2 36.4
99 DSYVGDEAQSK iTRAQ4plex@N-term; Lys->Gln@11 0.04 1341.62 671.82 1341.58 671.80 2 21.6 9.4 33.0 35.9
87 DSYVGDEAQSK iTRAQ4plex@N-term; Ser->Asp@10; iTRAQ4plex(K)@11 0.01 1513.72 505.58 1513.71 505.58 3 26.7 17.7 34.1 21.6
92 DSYVGDEAQSK iTRAQ4plex@N-term; Ser->Val@10; iTRAQ4plex(K)@11 0.01 1497.76 500.26 1497.76 500.26 3 27.3 25.1 28.8 18.8
99 DSYVGDEAQSKR iTRAQ4plex@N-term; iTRAQ4plex(K)@11 missed K-R@11 0.04 1641.86 548.29 1641.82 548.28 3 17.9 32.4 44.2 5.5
96 DSYVGDEAQSKR iTRAQ4plex@N-term; Lys->Gln@11 missed K-R@11 0.08 1497.76 500.26 1497.68 500.23 3 19.9 30.6 33.0 16.4
80 EITALAPSTMK Glu->pyro-Glu@N-term; iTRAQ4plex(K)@11 0.06 1286.76 644.39 1286.70 644.36 2 25.0 12.1 33.5 29.5
99 EITALAPSTMK iTRAQ4plex@N-term; Lys->Arg@11 0.01 1332.73 667.37 1332.72 667.37 2 19.8 11.4 33.8 35.0
89 EITALAPSTMK iTRAQ4plex@N-term; Lys->Gln@11 0.07 1304.75 653.38 1304.68 653.35 2 20.7 19.2 32.7 27.4
99 EITALAPSTMKI iTRAQ4plex@N-term; Lys->Ala@11; Ile->Ala@12 cleaved I-K@C-term; missed K-I@11 0.01 1318.70 660.36 1318.69 660.35 2 18.0 8.7 28.2 45.1
99 GYSFTTTAER iTRAQ4plex@N term 0 00 1275 63 638 82 1275 62 638 82 2 13 6 14 7 36 8 34 9- . . . . . . . . .
99 GYSFTTTAER iTRAQ4plex@N-term; Dimethyl(R)@10 0.05 1303.71 652.86 1303.65 652.83 2 22.5 6.8 32.6 38.0
99 HQGVMVGMGQK iTRAQ4plex@N-term; iTRAQ4plex(K)@11 0.00 1458.77 487.26 1458.77 487.26 3 14.5 30.6 37.5 17.4
90 HQGVMVGMGQK iTRAQ4plex@N-term; Lys->Arg@11 0.03 1342.70 448.57 1342.67 448.56 3 11.4 13.7 34.2 40.7
99 HQGVMVGMGQK iTRAQ4plex@N-term; Lys->Gln@11 0.05 1314.68 439.23 1314.63 439.22 3 14.2 22.0 31.8 32.0
99 KDLYANTVLSGGTTMYPGIADR iTRAQ4plex@N-term; iTRAQ4plex(K)@1 0.04 2630.40 658.61 2630.36 658.60 4 12.5 33.2 28.5 25.8
99 LDLAGRDLTDYLMK iTRAQ4plex@N-term; iTRAQ4plex(K)@14 missed R-D@6 0.01 1911.05 638.02 1911.04 638.02 3 40.6 15.9 32.7 10.8
98 MTQIMFETFNTPAMYVAIQAVLSLYASGR iTRAQ4plex@N-term 0.07 3396.77 850.20 3396.70 850.18 4 8.9 52.0 28.3 10.8
99 QEYDESGPSIVHR iTRAQ4plex@N-term 0.04 1659.84 554.29 1659.80 554.27 3 6.6 42.9 29.0 21.5
99 SYELPDGQVITIGNER iTRAQ4plex@N-term -0.02 1933.97 645.66 1933.99 645.67 3 11.2 41.0 30.4 17.5
99 SYELPDGQVITIGNER iTRAQ4plex@N-term; Asn->Arg@14 0.01 1976.05 659.69 1976.04 659.69 3 18.3 20.0 36.3 25.4
99 SYELPDGQVITIGNER iTRAQ4plex@N-term; Asp->Pro@6 -0.08 1915.93 639.65 1916.01 639.68 3 5.5 16.6 32.5 45.4
99 SYELPDGQVITIGNER iTRAQ4plex@N-term; Deamidated(N)@14; Glu->Arg@15 0.02 1962.05 655.02 1962.03 655.02 3 20.0 23.6 28.9 27.5
99 SYELPDGQVITIGNER iTRAQ4plex@N-term; Dehydrated(D)@6 -0.05 1915.93 639.65 1915.98 639.67 3 10.9 13.7 33.6 41.9
81 SYELPDGQVITIGNER iTRAQ4plex@N-term; Dehydrated(D)@6; Dimethyl(R)@16 0.01 1944.02 649.01 1944.01 649.01 3 13.0 21.2 41.0 24.8
99 SYELPDGQVITIGNER iTRAQ4plex@N-term; Dimethyl(R)@16 -0.01 1962.01 655.01 1962.02 655.01 3 18.6 14.0 37.5 29.9
99 TTGIVMDSGDGVTHTVPIYEGYALPH iTRAQ4plex@N-term cleaved H-A@C-term -0.04 2873.36 958.79 2873.40 958.81 3 7.7 19.7 30.5 42.0
99 TTGIVMDSGDGVTHTVPIYEGYALPHAILR iTRAQ4plex@N-term 0.04 3326.75 832.69 3326.71 832.68 4 24.8 20.5 29.3 25.4
99 TTGIVMDSGDGVTHTVPIYEGYALPHAILR iTRAQ4plex@N-term; Dimethyl(R)@30 -0.03 3354.72 839.69 3354.74 839.69 4 31.5 14.5 32.5 21.5
99 TVLSGGTTMYPGIADR iTRAQ4plex@N-term cleaved N-T@N-term 0.03 1781.94 594.99 1781.91 594.98 3 21.1 16.9 34.7 27.2
99 VAPEEHPVLLTEAPLNPK Carbamyl@N-term; iTRAQ4plex(K)@18 -0.04 2140.13 714.38 2140.17 714.40 3 1.1 67.1 19.4 12.4
93 VAPEEHPVLLTEAPLNPK Formyl@N-term; iTRAQ4plex(K)@18 -0.02 2125.14 709.39 2125.15 709.39 3 43.3 19.8 23.3 13.7
99 VAPEEHPVLLTEAPLNPK iTRAQ4plex@N-term; Lys->Arg@18 -0.04 2125.12 709.38 2125.17 709.40 3 20.6 24.9 33.5 21.0
99 VAPEEHPVLLTEAPLNPK iTRAQ4plex@N-term; Lys->Gln@18 0.01 2097.14 700.05 2097.12 700.05 3 13.8 21.1 35.2 29.9
99 YPIEHGIVTNWDDMEK iTRAQ4plex@N-term; Methyl(E)@4; iTRAQ4plex(K)@16 -0.01 2248.10 750.37 2248.11 750.38 3 10.8 27.0 39.8 22.4
Average: 19.1 21.6 31.8 27.5
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